Sudden death induced by intracoronary platelet aggregation

Area of Science:

• Cardiovascular Research
• Pharmacology
• Biochemistry

Background:

• Sodium arachidonate (AA) injection in rabbits induces cardiac events, including arrhythmia, ST-T depression, apnea, and mortality.
• Elevated levels of thromboxane B2 (TXB2) and 6-keto-PGF1 alpha are observed following AA administration.

Purpose of the Study:

• To investigate the role of thromboxane A2 (TXA2) in AA-induced sudden cardiac death.
• To evaluate the protective effects of aspirin (ASA) and TXA2 synthetase inhibitors against AA-induced mortality and cardiac ischemia.

Main Methods:

• Sodium arachidonate (1.5 mg/kg) was administered intravenously to rabbits.
• Groups were pretreated with aspirin (ASA) or TXA2 synthetase inhibitors (OKY-046 and 1581).
• Cardiac function, mortality, TXB2 and 6-keto-PGF1 alpha levels, and histological changes were assessed.

Main Results:

• AA injection caused significant mortality, arrhythmia, and ST-T depression.
• Pretreatment with ASA or TXA2 inhibitors abolished mortality and prevented significant changes in TXB2 levels.
• While 6-keto-PGF1 alpha increased in the OKY group, it remained unchanged in the ASA group, suggesting differential effects on prostacyclin production.
• Histological examination revealed reduced ischemic changes in pretreated groups.

Conclusions:

• TXA2 plays a critical role in AA-induced sudden cardiac death.
• Aspirin and TXA2 synthetase inhibitors offer significant protection against AA-induced cardiac events.
• Enhanced prostacyclin (PGI2) production may contribute to a protective mechanism against AA-induced thrombogenesis.